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(VS) is well documented in the literature, with tumour
growth being paramount to decision making for both
surveillance and treatment of these patients. Most previous
studies refer to the risk of VS growth over a given period of
time; however, this is not useful for counselling patients at
different stages of their follow-up, as the risk of tumour
growth is likely to be less following each subsequent year
that a tumour does not grow. Accordingly, we investigated
the conditional probability of VS growth at particular time-
points, given a patient has not grown thus far. This Bayesian
method of risk stratification allows for more tailored and
accurate approximations of the risk of growth versus
nongrowth of VS.
Methods: Retrospective analysis of a prospectively collected
database in a tertiary referral skull base unit, containing all
patients diagnosed between 2005 and 2014 with sporadic
unilateral VS and a minimum of 5-year surveillance.
Results: A total of 341 patients met the inclusion criteria.
The mean age at diagnosis was 67 years, the sizes of the VS
at diagnosis were intracanalicular in 49%, small in 39%,
medium in 11%, and large in 1%. Over the entire 5-year
surveillance period, a total of 139 tumours were seen to
grow (41%) and 202 did not grow (59%). At 1 year, thee and reprint requests to Manohar Bance,
ull Base Surgery, Addenbrooke’s Hospital,
spitals, Cambridge CB2 0QQ, UK; E-mail:
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000000000002448
logy, Inc.mour had not grown
to date was seen to be 21%, at 2 years 12%, at 3 years 9%,
at 4 years 3%, and at 5 years 2%. The conditional
probability of growth of extracanalicular VS was signifi-
cantly higher in the first year when compared with intracana-
licular VS (29% versus 13%, p¼ 0.01), but there was no
such difference in years 2, 3, 4 or 5 ( p¼ 0.60, 0.69, 0.36,
0.39, respectively).
Conclusion: This is the first study in the literature concerned
specifically with the conditional probability of VS growth.
The data presented here can be used to better inform VS
patients of their risk of growth at particular time points in
their disease—the longer VS have been observed to be
stable, the lower the risk of subsequent growth in a given
year. Further, an extracanalicular vestibular schwannoma is
more likely to grow in the first year compared with an
intracanalicular vestibular schwannoma. Our data also adds
support to surveillance protocols with increasingly infrequent
MRI scans, as after 4 years of not growing, the risk of
growth in year 5 falls to <2%. Key Words: Acoustic
neuroma—Conditional probability—Growth—Surveillance—
Vestibular schwannoma.
Otol Neurotol 40:xxx–xxx, 2019.INTRODUCTION
Vestibular schwannomas (VS) have a spectrum of
clinical manifestations, growth patterns and patient out-
comes. The observed incidence of VS has been steadily
increasing between 1976 and 2004, likely because of theimproved accessibility of MRI (1), the increased number
of indications for MRI that include the internal acoustic
meatus, and the higher resolution of MRI, which makes
intracanalicular VS more likely to be discovered. The
most recent studies, however, show that the incidence of
VS appears to be stabilizing at around 19 tumours per
million per year (2), approximately 2 per 100,000.
Clinically, the intracranial location of VS can cause
significant morbidity, with risks proportionate to the size,
location and growth rate of tumours. The natural growth
rate of VS has been relatively well studied, with the
literature suggesting that around 30–50% of newly diag-
nosed VS will grow during the first 5 years of follow-up
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pattern of VS (eg, slow versus fast growth, growth
followed by reduction versus growth followed by stabil-
ity) has been highly variable and no clear inferences can
be drawn at present (6–8).
In terms of management of VS, an increasingly prev-
alent strategy for small and medium-sized tumours is to
observe them from initial presentation with serial MRI
scans—the watch, wait and rescan (WWR) protocol. In
this, if there is no observed growth, the risks of surgery
and radiotherapy can be avoided. This strategy can,
however, lead to significant anxiety about VS growth
for patients and their relatives (9), and any data that can
help patients and clinicians understand the actual risk of
growth at different time points during the follow-up
trajectory would be valuable for clinical counselling
and decision making.
As such, the present study aims to answer the question
‘‘What is the probability that a VS will grow in a given
year, knowing that it has not grown for x number of years
already?’’. Most literature to date has assessed VS
growth risk over a given period of time; as such, patients
are quoted a generic probability of growth of their VS
over a particular time-period. However, we feel this lends
little helpful information when confronted with a patient
whose VS have not grown after, for example, 2 years.
Indeed, the risk of growing is seen to decrease with time,
such that growth risk is highest in the first year and then
decreases in each subsequent year (5,10).
There are some studies which have, en-passant, looked
at the cumulative probability of growth (or nongrowth)
over time (5,10). This does offer some additional infor-
mation for growth risks at specific times. However, these
methods do not take into account the a-priori information
of a tumour’s growth behaviour—that is to say, the
probability of the event (growth) is calculated as a
function of the total probability of the event. Thus, this
method represents a suboptimal statistical approach for
answering the question at hand. Instead, analysis by
conditional probability, a statistical method which
derives from Bayes’ theorem, would prove more fruitful.
In this methodology, the probability of an event is
calculated not as a function of the total probability of
the event, but rather as a function of the probability of
some prior event, here, nongrowth. This represents a
more informative approach to risk stratification of VS
patients at different stages in their disease timeline.
Specifically, the conditional probability is the probability
of VS growing, G, at a chosen timepoint, t, given that the
VS have not grown, N, in the years before this. As such, a
formula can be generalized as follows, which was used
for our analysis:
P Gt N t1j ;N t2 . . . N 1ð Þ ¼
P Gt \N t1 \N t2 . . . N 1ð Þ
P N t1 \N t2 . . . N 1ð Þ
Thus, the aim of the present study is to specify a
growth risk at a given time point, by taking into account
the known information that an individual’s VS have notOtology & Neurotology, Vol. 40, No. xx, 2019yet grown to date. The authors believe this information is
of much more clinical relevance compared with generic
risk approximations or cumulative probability. Further,
the study will look specifically at intracanalicular VS,
which have been reported to show a lower probability of
growth compared with extracanalicular tumours (10).
METHODS
A retrospective case review was undertaken using the pro-
spectively collected data in our local database in Adden-
brooke’s Hospital, Cambridge, UK, a tertiary referral centre.
Data were collected for all patients with sporadic unilateral VS
between 2005 and 2014. Selection criteria included those who
were initially managed conservatively (WWR) and who had a
minimum of 5 year’s surveillance imaging. Conservatively
managed patients tended to be those with smaller tumours
(<20 mm) or those with a performance status which precluded
surgery. In terms of imaging, the preferred MRI protocol was
1 mm slices of the internal acoustic meati using T1-weighted
gadolinium-enhanced MRI.
Exclusion criteria included those managed initially with
primary surgery or radiotherapy; this tended to be either those
with larger tumours or because of patient preference. We also
excluded those with neurofibromatosis type 2.
It is notable that in the study unit, surveillance imaging
conventionally took place at 6 months after the initial MRI,
annually for 3 years, then every 2 years for 6 years and every
3 years thereafter—as per the standard departmental VS imag-
ing protocol. Patient’s whose MRIs were not available for every
year over a 5-year period from diagnosis were excluded, except
in 2 special circumstances: First, where a gap in surveillance imaging was present, as
long as there was no difference in tumour size between
these scans, we assumed that the tumour did not grow in
the intervening time period. For example, if a patient had
scans at years 1, 3 and 5 from diagnosis, as long as no
growth was seen at these scans, we could assume there
was no growth over the entire 5-year period. Second, if a patient had a VS which grew on a particular
scan, as long as the preceding year’s scan was available,
then they were still included. This was because such an
arrangement still allowed tumour growth to be localized
to a specific year. For instance, if a patient had no
radiological evidence of growth at year 1 or 3, but
proceeded to show growth in year 4, then they were still
included because growth could be localized to year 4.
Conversely, a patient with stable scans at year 1 and 3, but
who showed growth at year 5, was excluded, as the
growth was not localizable—it could have taken place
in either year 4 or 5.We feel these criteria allowed us to form a representative
sample of patients. Many other units use similar criteria for
initial WWR and similar protocol for surveillance imaging, as
such, the cohort and data derived should be generalizable to
other units.
The data extracted from the database included age, sex,
recorded management, MRI dates, whether the tumour was
intracanalicular or extracanalicular and maximum intracranial
tumour diameter (ICTD) at each scan. Maximum ICTD is
recorded in the database in millimetres in the axial plane, based
on the review of MRI imaging by 2 specialized consultant
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THE CONDITIONAL PROBABILITY OF VESTIBULAR SCHWANNOMA GROWTH 3neuroradiologists. From this measurement, tumours were clas-
sified as intracanalicular, small (<15 mm ICTD), medium (15–
25 mm ICTD), or large (>25 mm ICTD). Change in tumour size
was then calculated by the difference between the maximum
ICTD for each scan compared with the initial scan. Owing to the
documented potential for interobserver error in recording
tumour dimensions (11), and in line with local criteria, VS
growth was predefined as an increase in the maximum ICTD of
2 mm or greater when compared with the initial MRI. For
comparison, data were also collected using a growth criterion
of 3 mm or greater (see Table 1).
Data were anonymized and stored on a password protected
trust computer, with analysis being undertaken using Python
Version 3.7.1 (Python Software Foundation) with package
SciPy (12).
Data analysis using conditional probability was undertaken,
using the formula outlined in the Introduction. Binomial confi-
dence intervals were calculated using the normal approximation
interval. Parametric data were analysed using the Student t-test.
Categorical data were analysed using the Chi-squared test.
RESULTS
Patient Demographics and Tumour Characteristics
There were 633 patients on the database between 2005
and 2014, of these, 341 met inclusion criteria. The most
common reason for exclusion was the failure to adhere to
our criteria of follow-up for 5 years. Of our cohort, there
were 191 (56%) male patients and 150 (44%) female
patients. The mean age at diagnosis was 67 years (stan-
dard deviation 12.4 years), range 33–63 years. The sizes
of the VS at diagnosis were intracanalicular in 49% (166
tumours), small in 39% (132 tumours), medium in 11%
(38 tumours) and large in 1% (5 tumours).
Growth
Of the total 341 tumours across the entire 5-year
surveillance period, a total of 139 VS were seen to grow













oldOf the 139 which grew; 59 were intracanalicular
(42%), 60 were small (43%), 17 were medium
(12%) and 3 were large (2%). In this group, 92
underwent subsequent intervention (66%), and ofE 1. Summary of the number of VS which exhibited growth versu
rowth)) for all, intracanalicular and extracanalicular tumours, for e
2-mm Growth Criteria
Conditional P(Growth)





73 268 21.4 13.3 29.1 47
33 235 12.3 11.1 13.7 25
22 213 9.36 10.1 8.41 20
7 206 3.29 4.35 2.04 6
4 202 1.94 2.73 1.04 3
values used to highlight the key percentages presented in this paper. That ithese 24 had surgical management (17%) and 68
converted to radiotherapy (49%). Of the 202 that did not show any growth; 107
were intracanalicular (53%), 72 were small
(36%), 21 were medium (10%) and 2 were large
(1%).This information is summarized in Figure 1. No sig-
nificant difference was found in tumour sizes between
those that grew versus those that did not grow ( p¼ 0.26).
Using the Bayesian approach, the conditional proba-
bility of growth between year 0 and 1 was seen to be 21%
(95% confidence interval [CI] 17–26). Henceforth, ‘at
year t’ will refer to growth between year t1 and year t. If
VS had not grown in 1 year, then the probability of
growth at 2 years was 12% (95% CI 9–17), and at 3 years
9% (95% CI 6–14), at 4 years 3% (95% CI 1–7), and at
5 years 2% (95% CI 0.5–5), this is summarized in
Table 1 and Figure 2.
The data were then fitted using a nonlinear least-square
regression to an exponential equation, to yield a regres-
sion line, plotted in Figure 2. Regression characteristics,
RMSE¼ 1.04 and r2¼ 0.98, indicate a good fit by
the model.
The conditional probability of growth for intracana-
licular versus extracanalicular VS was also calculated,
summarized in Table 1 and Figure 3. For intracanalicular tumours: at 1 year, the condi-
tional probability of growth was seen to be 13%, at
2 years 11%, at 3 years 10%, at 4 years 4%, and at
5 years 3%. For extracanalicular tumours: at 1 year, the condi-
tional probability of growth was seen to be 29%, at
2 years 14%, at 3 years 8%, at 4 years 2%, and at
5 years 1%.The conditional probability of growth of extracana-
licular VS was seen to be significantly higher in the first
year when compared with intracanalicular VS (29%
versus 13%, p¼ 0.01), but there was no such difference
in years 2, 3, 4 or 5 ( p¼ 0.60, 0.69, 0.36, 0.39, respec-
tively).s nongrowth, and the conditional probability of growth
ach year, for both a 2-mm and 3-mm growth criteria
3-mm Growth Criteria
Conditional P(Growth)





294 13.8 13.3 14.3
269 8.50 9.72 7.33
249 7.43 10.0 5.04
243 2.41 4.27 0.76
240 1.23 2.68 0.00
s, the conditional probability of growth at each year.
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FIG. 1. Nested Pie Chart illustrating proportion of 341 cohort demonstrating Growth compared to No Growth, and the sizes of vestibular
schwannoma seen in each group (IC – intracanalicular, S – small, M – medium, L – large).
FIG. 2. Conditional probability of growth at given times from diagnosis (solid), annotated with data values, and least squares regression
model of VS growth at given time points for 15 (dashed).
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FIG. 3. Conditional probability of growth at given times from diagnosis, split by all vestibular schwannomas (VS) (solid), intracanalicular VS
(dashed) and extracanalicular VS (dotted).
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The natural history of VS has been explored through a
number of studies, with the often-quoted growth rate
being around 30–50% over 5 years (3–5). However, we
feel that this lends little helpful information when con-
fronted with a patient whose VS have not grown after, for
example, 2 years. Indeed, one could predict that the
longer VS have been observed to be stable, the lower
the risk of subsequent growth in a given year and others
have shown this to be the case (5,10). Our data lend
evidence to this assertion in more detail, by estimating
the conditional probability of growth at given time
points. We found that at 1 year, the conditional proba-
bility of growth was seen to be 21%, at 2 years 12%, at
3 years 9%, at 4 years 3%, and at 5 years 2%. Thus, a
patient is most likely to grow within their first year after
diagnosis, but for each subsequent year of nongrowth, the
VS become increasingly less likely to grow.
If the present data are analysed in a cumulative statis-
tical manner it would allow comparison with data
obtained in other centres. Data in sufficient detail were
only available for Stangerup et al (1), with the compari-
son shown in Figure 4. Note that the present study
defined growth by a change in ICTD by 2 mm, compared
with the 3-mm used by Stangerup. However, in Figure 4,
we plot the results for both a 2-mm and 3-mm criteria
for growth.As explained in the Introduction, the previous studies
looking at cumulative probability are statistically less
accurate, and one might expect an underestimate of
the probability of growth in these studies as a result.
Further, one might also predict that this underestimation
be greatest in the latter years of follow-up. This is
because the minimum number of follow-up scans was
just 2 years in these studies, and so it is likely more
patients will have had a scan at year 1 than at year 5.
Therefore, at 1 year, where more patients have scans, a
larger subgroup would be included in the probability
calculation, and the results are more likely to lie closer
to the true value for the cohort as a whole. Conversely, at
year 5, it is less likely for patients to have had a scan,
meaning a smaller subgroup is formed and so there is a
greater assumption that all unaccounted patients are
nongrowers, leading to a larger difference from the
true risk.
From Figure 4, we see that at each time point the
cumulative probability of growth is less for the Stangerup
study compared with the present study, as predicted. The
exception to this is at the 1-year growth risk, which was
actually seen to be marginally less in the present data
when using the equivalent 3 mm growth cut-off—per-
haps reflecting an approximation to the true value in both
studies. In addition, the underestimation in Stangerup’s
data becomes greater with an increasing length of follow-
up, as anticipated.Otology & Neurotology, Vol. 40, No. xx, 2019
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FIG. 4. Comparison of present data where cumulative probability of growth is defined by a change in intracranial tumour diameter of 2 mm
(dotted) or 3 mm (dashed), with study by Stangerup et al using 3 mm (solid).
6 M. SETHI ET AL.As previously mentioned, methods used by Stangerup
could have led to the formation of subgroups because of
inconsistent scan intervals, and the subsequent statistical
assumption that all patients who were unaccounted for in
a given year were nongrowers. This was mitigated in the
present study by our statistical methodology and at least
5-year minimum follow-up period, and as such we
believe our results are likely to represent the true risks
of VS growth in our cohort. It is also interesting to note
that the overall shapes of the curves are similar, espe-
cially when the same definition of growth is used (3 mm),
and there was no significant difference in cumulative
probability of growth between these 2 groups ( p¼ 0.68)
suggesting that the groups in both studies are comparable
and that the results presented here are generalizable to
other units.
The information presented here can be used to specifi-
cally inform decision making for both the physician and
patient in WWR protocols. For instance, knowing one’s
tumour has not grown for 4 years, leads to an observed
probability of growth in year 5 of <2%. This information
can be used to reassure a patient that growth is very
unlikely, and second, can prompt discussions about sur-
veillance frequency. There are a number of studies dem-
onstrating VS growth after many years of follow-up
(7,13,14) with the subsequent recommendation being of
lifelong surveillance (albeit with increasing time intervals
between scans). The spacing out of scanning intervals
would be supported by the data presented here.Otology & Neurotology, Vol. 40, No. xx, 2019Although we only have data for the first 5 years of
follow-up in our cohort, a fitted regression model can be
used to predict the conditional probability of growth at
time-points beyond this—shown in Figure 5 for both 2
and 3-mm growth criteria. Accepting that commenting
beyond this time point is speculative, one would expect a
trend of sequentially reducing conditional probability of
growth to continue. From the model, a conditional prob-
ability of growth of 1% occurs at 6 years 10 months for a
2-mm growth criteria, and 6 years 8 months for 3-mm
growth criteria, or put another way, from 7 years onwards
the risk of growth in any subsequent year would be<1%.
This 1% cut-off is often used by units in deciding when to
discontinue surveillance, and as such the model would
have implications for the most appropriate protocol for
surveillance; however, this is an ongoing discussion (14–
16) beyond the scope of this article. It would be useful to
compare the predictive model presented here with future
studies of conditional probability to determine the accu-
racy of this regression analysis.
Further, the conditional probability of growth of
extracanalicular VS was seen to be significantly higher
in the first year when compared with intracanalicular VS
(29% versus 13%, p¼ 0.01), but there was no such
difference in years 2, 3, 4 or 5. Interestingly, this is
not consistent with a recent systematic review which
analysed the effect of various factors on tumour growth,
finding that patient age, sex and tumour size at presenta-
tion did not influence VS growth (3). However, we feel
CE: S.W.; MAO/ON-19-302; Total nos of Pages: 8;
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FIG. 5. Regression model showing predicted conditional probability of growth for 1 x10 for both 2 mm (left) and 3 mm (right) growth
criteria.
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on Bayesian analysis, looking at growth rates within a
particular year, whereas in previous studies, the grouping
of risk over a 3 or 5-year span is likely to have hidden
this difference.
The results presented here are from a single-centre
study, resulting in a medium-sized cohort of patients.
This was compounded by the fact that the local WWR
protocol does not include annual scans for 5 years, which
excluded a great deal of patients from the study. Most of
the data, therefore, came from patients who had followed
an alternate protocol (not selected for any systematic
reasons that we could discern), so that we had complete
data and times for growth over the whole 5-year period.
This could perhaps present a selection bias, however,
given the comparable results of Stangerup et al (1), we
feel this is unlikely to be the case. All data were obtained
from our local database, as such, dates and measurements
are reliant on correct input into this database which is of
course prone to human error. The maximum ICTD was
based on approved MRI reports from experienced spe-
cialized neuroradiologists; however, these measurements
were taken in a linear plane (axial, sagittal and coronal)
rather than at the widest point in any other virtual
plane, which may limit the measurement accuracy of
VS dimensions.
Conversely, a number of study strengths lend credibil-
ity to the results observed. Despite a smaller cohort than
all VS patients that were available, our rigorous exclu-
sion criteria of follow-up over 5 years, meant that the data
were very homogenous and all patients had scans which
allowed temporal localization of growth. As such, no
inferences were needed to be made about the exact period
in which a tumour grew. The database used was retro-
spectively accessed, but data are entered prospectively
and are thus free of referral bias and a-priori selection
bias. Our cohort only included patients who had been
assigned to treatment in the WWR protocol based on thesize of the tumour, and more rarely because of other
reasons (such as comorbidities or symptoms). Given that
this type of stratification is true in every centre, we
believe that the results from our cohort are likely to be
representative of the population of patients with VS.
CONCLUSION
This is the first study in the literature concerned
specifically with the conditional probability of VS
growth. The data presented here can be used to better
inform VS patients of their risk of growth at particular
time points in their disease course—at 1 year 21%, at
2 years 12%, at 3 years 9%, at 4 years 3%, and at 5 years
2%. This highlights that the longer VS have been
observed to be stable, the lower the risk of subsequent
growth in a given year. Further, an extracanalicular
vestibular schwannoma is more likely to grow in the
first year compared with an intracanalicular vestibular
schwannoma (29% versus 13%, p¼ 0.01). Our data also
adds support to surveillance protocols with increasingly
infrequent MRI scans, as after 4 years of not growing, the
risk of growth in year 5 falls to <2%.
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